Neuca

Neuca FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Neuca (NEU.WA) as of Oct 21, 2026 is 238.89 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was -19.24 % — a change of -1,341.48% (higher).

FCF Conversion

238.89 %

YoY

-1,341.48%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Neuca is 2025 238.89 % . FCF Conversion Rate (FCF/EBITDA) of Neuca was 2024 -19.24 % . It decreases by -1,341.48% higher compared to the previous year.

The Neuca FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2018
12.04 PLN
Jan 1, 2019
68.80 PLN
Jan 1, 2020
168.92 PLN
Jan 1, 2021
164.25 PLN
Jan 1, 2022
185.44 PLN
Jan 1, 2023
132.69 PLN
Jan 1, 2024
-19.24 PLN
Jan 1, 2025
238.89 PLN
The Neuca FCF Conversion history
YEARFCF ConversionYoY
238.89 %-1,341.48%
-19.24 %-114.50%
132.69 %-28.44%
185.44 %+12.90%
164.25 %-2.77%
168.92 %+145.52%
68.80 %+471.30%
12.04 %-81.97%
66.81 %-42.62%
116.44 %-20.84%
147.09 %-17.32%
177.90 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Neuca Stock analysis

What does Neuca do? NEUCA SA generates revenue through the wholesale distribution of pharmaceutical products to pharmacies, leveraging its extensive network in the health market. The company also produces and sells its own branded drugs, supplements, and cosmetics, while offering clinical trials, telemedicine services, and IT solutions tailored for healthcare providers. Its e-commerce platform further supports the healthcare industry by enabling digital transactions for medical products and services. The primary buyers include pharmacies, healthcare institutions, and consumers seeking health-related products through online channels. NEUCA SA's business model integrates multiple revenue streams within the health sector, with a focus on both physical and digital distribution. The firm's own-brand products, such as pharmaceuticals and cosmetics, are sold directly to end-users and retail partners, while its IT solutions and telemedicine services target healthcare organizations. Clinical trials represent another key segment, attracting partnerships with research institutions and pharmaceutical firms. The company's operational scope spans from production to distribution, ensuring a comprehensive approach to healthcare market needs. The company's revenue is driven by its diversified portfolio, including drug distribution, branded product sales, and specialized services like telemedicine and clinical trials. Pharmacies remain the core customer segment for its wholesale operations, while e-commerce and IT solutions cater to a broader audience of healthcare providers and consumers. NEUCA SA's strategic positioning in the health market allows it to capitalize on multiple growth areas without relying on a single revenue source. Neuca is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Neuca stock

FCF Conversion Rate (FCF/EBITDA) of Neuca is 238.89 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of Neuca changed from -19.24 % to 238.89 %, representing a -1,341.48% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Neuca since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Neuca with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Neuca

All Key Metrics — Neuca